{
    "clinical_study": {
        "@rank": "144547", 
        "acronym": "CLMF237A1303", 
        "arm_group": [
            {
                "arm_group_label": "LMF237", 
                "arm_group_type": "Experimental", 
                "description": "Patients should take LMF237 50/250 mg twice daily or LMF237 50/500 mg (with a starting dose of LMF 237 50/250 mg for 2 weeks) twice daily, switching from vildagliptin 50 mg twice daily"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Patients should take matching placebo of LMF237 (vildagliptin 50 mg) twice daily, switching from vildagliptin 50 mg twice daily"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of the study is to evaluate the efficacy and safety of LMF237 50/250 mg and\n      50/500 mg bid in Japanese patients with T2DM inadequately controlled with vildagliptin\n      monotherapy. This study is being conducted to support registration of the fixed-dose\n      combination of vildagliptin and metformin for the treatment of T2DM in Japan."
        }, 
        "brief_title": "Study of Efficacy and Safety LMF237 in Patients With Type 2 Diabetes Mellitus (T2DM) Inadequately Controlled With Vildagliptin Monotherapy", 
        "completion_date": {
            "#text": "February 2014", 
            "@type": "Actual"
        }, 
        "condition": "Diabetes Mellitus, Type 2", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients with type 2 diabetes inadequately controlled with diet, exercise and oral\n             anti-diabetic therapy\n\n          -  HbA1c in the range of 7.0-10.0%\n\n          -  Body mass index in the range of 20-35 kg/m^2\n\n        Exclusion Criteria:\n\n          -  Type 1 diabetes, monogenic diabetes, diabetes resulting from pancreatic injury, or\n             secondary forms of diabetes\n\n          -  Significant heart diseases Other protocol-defined inclusion/exclusion criteria may\n             apply"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "74 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "171", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "March 12, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01811485", 
            "org_study_id": "CLMF237A1303"
        }, 
        "intervention": [
            {
                "arm_group_label": "LMF237", 
                "description": "Corresponds to vildagliptin 50 mg twice daily and metformin 250 mg twice daily", 
                "intervention_name": "LMF237 50/250 mg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "LMF237", 
                "description": "Corresponds to vildagliptin 50 mg twice daily and metformin 500 mg twice daily", 
                "intervention_name": "LMF237 50/500 mg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Matching placebo of LMF237 (vildagliptin 50 mg) twice daily", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Vildagliptin"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "February 24, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Chikushino-city", 
                        "country": "Japan", 
                        "state": "Fukuoka", 
                        "zip": "818-0083"
                    }, 
                    "name": "Novartis Investigative Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Fukuoka-city", 
                        "country": "Japan", 
                        "state": "Fukuoka", 
                        "zip": "819-0006"
                    }, 
                    "name": "Novartis Investigative Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Fukuoka-city", 
                        "country": "Japan", 
                        "state": "Fukuoka", 
                        "zip": "810-0014"
                    }, 
                    "name": "Novartis Investigative Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Iizuka", 
                        "country": "Japan", 
                        "state": "Fukuoka", 
                        "zip": "820-8505"
                    }, 
                    "name": "Novartis Investigative Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kitakyushu", 
                        "country": "Japan", 
                        "state": "Fukuoka", 
                        "zip": "800-0296"
                    }, 
                    "name": "Novartis Investigative Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kitakyushu-city", 
                        "country": "Japan", 
                        "state": "Fukuoka", 
                        "zip": "807-0857"
                    }, 
                    "name": "Novartis Investigative Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Koga-city", 
                        "country": "Japan", 
                        "state": "Ibaraki", 
                        "zip": "306-0232"
                    }, 
                    "name": "Novartis Investigative Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kawasaki", 
                        "country": "Japan", 
                        "state": "Kanagawa", 
                        "zip": "210-0852"
                    }, 
                    "name": "Novartis Investigative Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Yokohama-city", 
                        "country": "Japan", 
                        "state": "Kanagawa", 
                        "zip": "221-0802"
                    }, 
                    "name": "Novartis Investigative Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Yokohama-city", 
                        "country": "Japan", 
                        "state": "Kanagawa", 
                        "zip": "231-0023"
                    }, 
                    "name": "Novartis Investigative Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Yatsushiro", 
                        "country": "Japan", 
                        "state": "Kumamoto", 
                        "zip": "866-8660"
                    }, 
                    "name": "Novartis Investigative Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Yatsushiro-city", 
                        "country": "Japan", 
                        "state": "Kumamoto", 
                        "zip": "866-8533"
                    }, 
                    "name": "Novartis Investigative Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kyoto-city", 
                        "country": "Japan", 
                        "state": "Kyoto", 
                        "zip": "615-0035"
                    }, 
                    "name": "Novartis Investigative Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sakai-city", 
                        "country": "Japan", 
                        "state": "Osaka", 
                        "zip": "590-0064"
                    }, 
                    "name": "Novartis Investigative Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Takatsuki-city", 
                        "country": "Japan", 
                        "state": "Osaka", 
                        "zip": "569-1096"
                    }, 
                    "name": "Novartis Investigative Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ageo-city", 
                        "country": "Japan", 
                        "state": "Saitama", 
                        "zip": "362-8588"
                    }, 
                    "name": "Novartis Investigative Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tokorozawa-city", 
                        "country": "Japan", 
                        "state": "Saitama", 
                        "zip": "359-1161"
                    }, 
                    "name": "Novartis Investigative Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bunkyo-ku", 
                        "country": "Japan", 
                        "state": "Tokyo", 
                        "zip": "113-0031"
                    }, 
                    "name": "Novartis Investigative Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Edogawa-ku", 
                        "country": "Japan", 
                        "state": "Tokyo", 
                        "zip": "134-0084"
                    }, 
                    "name": "Novartis Investigative Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hachioji", 
                        "country": "Japan", 
                        "state": "Tokyo", 
                        "zip": "192-0046"
                    }, 
                    "name": "Novartis Investigative Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hachioji-city", 
                        "country": "Japan", 
                        "state": "Tokyo", 
                        "zip": "192-0918"
                    }, 
                    "name": "Novartis Investigative Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Katsushika-ku", 
                        "country": "Japan", 
                        "state": "Tokyo", 
                        "zip": "124-0024"
                    }, 
                    "name": "Novartis Investigative Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kiyose", 
                        "country": "Japan", 
                        "state": "Tokyo", 
                        "zip": "204-0021"
                    }, 
                    "name": "Novartis Investigative Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Minato-ku", 
                        "country": "Japan", 
                        "state": "Tokyo", 
                        "zip": "108-0075"
                    }, 
                    "name": "Novartis Investigative Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Minato-ku", 
                        "country": "Japan", 
                        "state": "Tokyo", 
                        "zip": "105-7390"
                    }, 
                    "name": "Novartis Investigative Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nerima-ku", 
                        "country": "Japan", 
                        "state": "Tokyo", 
                        "zip": "177-0051"
                    }, 
                    "name": "Novartis Investigative Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Shibuya-ku", 
                        "country": "Japan", 
                        "state": "Tokyo", 
                        "zip": "150-0002"
                    }, 
                    "name": "Novartis Investigative Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Shinagawa-ku", 
                        "country": "Japan", 
                        "state": "Tokyo", 
                        "zip": "141-0032"
                    }, 
                    "name": "Novartis Investigative Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Toshima-ku", 
                        "country": "Japan", 
                        "state": "Tokyo", 
                        "zip": "171-0021"
                    }, 
                    "name": "Novartis Investigative Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kyoto", 
                        "country": "Japan", 
                        "zip": "607-8062"
                    }, 
                    "name": "Novartis Investigative Site"
                }
            }
        ], 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Multicenter, Double-Blind, Randomized, Parallel-Group Study to Compare the Effect of 14 Weeks Treatment With LMF237 Bid to Placebo in Patients With Type 2 Diabetes Inadequately Controlled With Vildagliptin 50 mg Bid Monotherapy", 
        "overall_official": {
            "affiliation": "Novartis Pharmaceuticals", 
            "last_name": "Novartis Pharmaceuticals", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Japan: Ministry of Health, Labor and Welfare", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "February 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "HbA1c will be performed on a blood sample obtained and measured by High performance liquid chromatography  (HPLC) performed at a central laboratory.", 
            "measure": "Change from baseline in glycosylated hemoglobin (HbA1c) at 14 weeks between treatment groups", 
            "safety_issue": "No", 
            "time_frame": "Baseline to 14 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01811485"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "HbA1c will be performed on a blood sample obtained and measured by HPLC performed at a central laboratory.", 
                "measure": "Change from baseline in HbA1c at 14 weeks within each dose strength", 
                "safety_issue": "No", 
                "time_frame": "Baseline to 14 weeks"
            }, 
            {
                "description": "Responder rates will be analyzed in categories:\nEndpoint HbA1c \u2264 6.5%\nEndpoint HbA1c < 7%\nEndpoint HbA1c < 7% in patients with baseline HbA1c \u2264 8%\nEndpoint HbA1c < 6.9%\nHbA1c reduction from baseline at endpoint \u2265 1%\nHbA1c reduction from baseline at endpoint \u2265 0.5%", 
                "measure": "Percentage of patients meeting Responder rates in HbA1c", 
                "safety_issue": "No", 
                "time_frame": "14 weeks"
            }, 
            {
                "description": "FPG will be performed on a blood sample obtained and analyzed at a central laboratory.", 
                "measure": "Change from baseline in Fasting plasma glucose (FPG) at 14 weeks", 
                "safety_issue": "No", 
                "time_frame": "Baseline to 14 weeks"
            }, 
            {
                "description": "The occurrence of adverse events will be sought by non-directive questioning of the patient at each visit. Adverse events are defined as appearance or worsening of any undesirable symptom, sign (including an abnormal laboratory finding), or medical conditions. Serious adverse events are any untoward medical occurrences that result in death, are life threatening, require (or prolong) hospitalization, cause persistent or significant disability/incapacity, result in congenital anomalies or birth defects, or are other conditions which in judgment of investigators represent significant hazards.", 
                "measure": "Number of patients with adverse events (including hypoglycemia), serious adverse events and death", 
                "safety_issue": "Yes", 
                "time_frame": "14 weeks"
            }
        ], 
        "source": "Novartis", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novartis Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}